MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 6, 2018, the Compensation Committee of the Board of Directors of Moleculin Biotech, Inc. (“Company”) completed its annual review of executive compensation for the 2017/2018 compensation year (June 1, 2017 to May 31, 2018). After researching comparable companies and using a leading industry survey, the Compensation Committee recommended to the Board of Directors, and after receiving the recommendation, the Board of Directors approved the following compensation arrangements with its named executive officers for the 2018/2019 compensation year (June 1, 2018 to May 31, 2019):
|
For the 2017/2018 compensation year, Walter V. Klemp, Chief Executive Officer, was granted a cash bonus award of $138,250 and was issued a 10-year option to purchase 603,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 4-year annual vesting (i.e., one-quarter of grant vests on the first, second, third and fourth anniversary of the issuance date) and an exercise price equal the closing price of the Company's common stock on the date of approval, or $1.82 per share. For the 2018/2019 compensation year, Mr. Klemp’s base compensation was increased to $440,000, his targeted cash bonus for such year was set at 55% of base compensation, and his targeted option grant value for such year was set at $800,000; provided that the cash bonus and option grants for the compensation year are subject to Compensation Committee approval. |
|
For the 2017/2018 compensation year, Jonathan P. Foster, Chief Financial Officer, was granted a cash bonus award of $105,300 and was issued a 10-year option to purchase 301,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 4-year annual vesting (i.e., one-quarter of grant vests on the first, second, third and fourth anniversary of the issuance date) and an exercise price equal the closing price of the Company's common stock on the date of approval, or $1.82 per share. For the 2018/2019 compensation year, Mr. Foster’s base compensation was increased to $340,000, his targeted cash bonus for such year was set at 40% of base compensation, and his targeted option grant value for such year was set at $315,000; provided that the cash bonus and option grants for the compensation year are subject to Compensation Committee approval. |
|
For the 2017/2018 compensation year, Donald Picker, Chief Science Officer, was granted a cash bonus award of $54,510 and was issued a 10-year option to purchase 75,000 shares of the Company's common stock, under the Company's 2015 Stock Plan, with 4-year annual vesting (i.e., one-quarter of grant vests on the first, second, third and fourth anniversary of the issuance date) and an exercise price equal the closing price of the Company's common stock on the date of approval, or $1.82 per share. For the 2018/2019 compensation year, Dr. Picker’s base compensation will be $275,000, his targeted cash bonus for such year was set at 41% of base compensation, and his targeted option grant value for such year was set at $100,000; provided that the cash bonus and option grants for the compensation year are subject to Compensation Committee approval. |
Item 5.07Submission of Matters to a Vote of Security Holders.
On June 6, 2018, Moleculin Biotech, Inc. held its 2017 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 25, 2018, the record date for the Annual Meeting, there were 25,768,861 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 21,717,041, or 84.27%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each
share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.
Proposal 1. The Company's stockholders elected Walter V. Klemp, Robert George, Michael Cannon and John Climaco each to serve until the 2019 annual meeting of stockholders of the Company or until such person's successor is qualified and elected. The voting for each director was as follows:
|
Director Name |
Votes For |
Votes Withheld |
Broker Non-Votes |
|
Walter V. Klemp |
9,682,963 |
142,471 |
11,891,607 |
|
Robert George |
9,316,137 |
509,297 |
11,891,607 |
|
Michael Cannon |
9,342,171 |
483,263 |
11,891,607 |
|
John Climaco |
9,708,268 |
117,166 |
11,891,607 |
Proposal 2. The Company's stockholders ratified the appointment of Grant Thornton, LLP as the Company's Independent registered public accounting firm for the fiscal year ending December 31, 2018, by the following vote:
|
Votes For |
Votes Against |
Abstain |
|
21,223,813 |
234,112 |
259,116 |
Proposal 3. The Company's stockholders authorized the Board of Directors, in its sole discretion, prior to the one-year anniversary of the Annual Meeting, to file an amendment to the Company's Certificate of Incorporation to effect a reverse stock split at one of the following reverse stock split ratios, 1-for-2, 1-for-3, 1-for-4, or 1-for-5. As of the date hereof, the Company's Board of Directors has not made any determination on the filing of such amendment. The voting on this proposal is set forth below:
|
Votes For |
Votes Against |
Abstain |
|
16,630,159 |
4,773,195 |
313,687 |
Proposal 4. The Company's stockholders approved the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of Proposal 3, the reverse stock split. The voting on this proposal is set forth below:
|
Votes For |
Votes Against |
Abstain |
|
17,517,241 |
3,909,718 |
290,082 |
Adjournment of the Annual Meeting was not necessary or appropriate because there were sufficient votes in favor of Proposal 3.
Proposal 5. The Company's stockholders approved the amendment to the Company's 2015 stock plan. The voting on this proposal is set forth below:
|
Votes For |
Votes Against |
Abstain |
Broker Non-Votes |
|
8,823,152 |
939,044 |
63,238 |
11,891,607 |
About MOLECULIN BIOTECH, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.
